Everything below concerns Selank. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Characterization of Selank in laboratory settings relies on standard peptide analytical techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and degradation products, while mass spectrometry confirms molecular identity through accurate mass measurement. Amino acid analysis and peptide sequencing verify the primary structure when reference material is unavailable. Because Selank is a short chain, fragmentation-based analysis produces a diagnostic ion pattern that supports confident identification.
Peptide stability depends strongly on temperature, moisture, and pH. Lyophilized Selank is generally most stable when stored cold and dry, with freezer temperatures commonly used for long-term storage. In solution, the compound is susceptible to hydrolysis and to microbial growth if it is not handled aseptically. The C-terminal proline-rich extension appears to slow enzymatic cleavage relative to tuftsin, though quantitative degradation rates vary with the matrix and the conditions tested. Published stability data specific to Selank remain sparse.
| Property | Value | Notes |
|---|---|---|
| Primary route studied | Intranasal | Also examined parenterally in animal work |
| Reported plasma half-life | Minutes to tens of minutes | Values vary widely between reports |
| Main model systems | Rodent behavioural and cell assays | Human trials are few and small |
| Principal proposed targets | GABA-A receptor, GABA transaminase | Monoamine and neurotrophic pathways also reported |
| Evidence grade | Preliminary | Limited independent replication |
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
The first body segment (segment number 1) features both the earthworm's mouth and, overhanging the mouth, a fleshy lobe called the prostomium, which seals the entrance when the worm is at rest, but is also used to feel and chemically sense the worm's surroundings. Some species of earthworm can even use the prehensile prostomium to grab and drag items such as grasses and leaves into their burrow. An adult earthworm develops a belt-shaped glandular swelling, called the clitellum, which covers several segments toward the front part of the animal. This is part of the reproductive system and produces egg capsules. The posterior segment is most commonly cylindrical like the rest of the body, but depending on the species, it may also be quadrangular, octagonal, trapezoidal, or flattened. The last segment is called the periproct; the earthworm's anus, a short vertical slit, is found on this segment.
=== International sanctions === In response to Iran's nuclear and ballistic missile advancements, as well as its backing of militant organizations that compromise regional peace, the United States, in conjunction with a network of international allies, has imposed a rigorous sanctions regime. This multifaceted approach extends beyond Iran’s military activities, with its record of human rights abuse further justifying the global punitive measures. The sanctions have specifically targeted Iran's crucial oil sector and banking systems, which are central to its economy. As a result, these measures have significantly undermined the nation's ability to earn foreign currency, dealing a critical blow to its economic infrastructure and foreign trade relationships. This limitation has considerably impeded Iran's capacity to import essential food products and agricultural inputs, including seeds, fertilizers, and machinery. Consequently, the sanctions have led to increased production costs and higher food prices. Furthermore, the disruption of critical supply chains has increased transportation expenses, intensifying inflationary pressures within the country.
Trump's administration strained relations with South Africa. Trump suspended all aid to South Africa, saying the country's land expropriation law discriminated against Afrikaners; he also offered Afrikaners refugee status in the U.S. Rubio refused to attend the G20 foreign ministers' meeting in Johannesburg and he declared the South African ambassador persona non grata for his criticism of U.S. policies.
Sources: en.wikipedia.org
== Using data obtained to find concentration of unknown == In summary, in order to find a standard curve, one must use varying concentrations of BSA (Bovine Serum Albumin) in order to create a standard curve with concentration plotted on the x-axis and absorbance plotted on the y-axis. Only a narrow concentration of BSA is used (2-10 ug/mL) in order to create an accurate standard curve. Using a broad range of protein concentration will make it harder to determine the concentration of the unknown protein. This standard curve is then used to determine the concentration of the unknown protein. The following elaborates on how one goes from the standard curve to the concentration of the unknown. First, add a line of best fit, or Linear regression and display the equation on the chart. Ideally, the R2 value will be as close to 1 as possible. R represents the sum of the square values of the fit subtracted from each data point. Therefore, if R2 is much less than one, consider redoing the experiment to get one with more reliable data.
Bringing Sarafem to market harmed Lilly's reputation in some quarters. The diagnostic category of PMDD was controversial since it was first proposed in 1987, and Lilly's role in retaining it in the appendix of the DSM-IV-TR, the discussions for which began in 1998, has been criticized. Lilly was accused of inventing a disease to make money, and for not innovating but rather just seeking ways to continue making money from existing drugs. It was also criticized by the FDA and groups concerned with women's health for marketing Sarafem too aggressively when it was first launched; the campaign included a television commercial featuring a harried woman at the grocery store who asks herself if she has PMDD.
=== Clean energy roll-back === The bill was described by The New York Times as derailing renewable energy production and research in the United States, and possibly ceding the clean energy race to China. Its policies favor fossil fuel companies over renewable energy such as solar, wind, and EV manufacturing, and are expected to lead to large clean energy job losses, factory closures, and deter investment in clean technologies. Specifically, the law phases out most clean-energy tax incentives introduced under the Biden-era Inflation Reduction Act such as credits for low-carbon electricity (wind, solar), electric vehicle rebates, home electrification, clean hydrogen, and domestic manufacturing of batteries and solar panels. The law rescinds various IRA funds for grants related to freeway removal improving biking and walking in poorer neighborhoods, electric truck and bus manufacturing, faster state and local environmental reviews and place-based green industrial policy and home electrification. An April 2026 study projected the IRA's impact on clean energy investments would be nearly wiped out by the OBBBA, and emissions would be reduced by only 34 percent below 2005 levels, compared to 44 percent with the IRA. A report released by environmental group BlueGreen Alliance found that the OBBBA caused 223 manufacturing and clean energy projects to stall or be cancelled, affecting over 111,000 jobs and $82.9 billion in investment.
==== Australian Information Commissioner inquiry ==== In December 2023, the Office of the Australian Information Commissioner announced an inquiry into TikTok's data harvesting of Australian citizens amid allegations that it contravened Australian privacy law.
Sources: en.wikipedia.org
=== Commanding officers === 1950 Lt Col Mike Calvert, Royal Engineers 1951 Lt Col John Sloane, Argyll and Sutherland Highlanders 1953 Lt Col Oliver Brooke, Welch Regiment 1954 Lt Col Michael Osborn, West Yorkshire Regiment 1955 Lt Col George Lea, Lancashire Fusiliers and Parachute Regiment 1957 Lt Col Tony Deane-Drummond, Royal Signals 1960 Lt Col Ronald Dare Wilson, Royal Northumberland Fusiliers 1962 Lt Col John Woodhouse, Dorset Regiment and East Surreys 1965 Lt Col Michael Wingate-Gray, Black Watch 1967 Lt Col John Slim, Argyll and Sutherland Highlanders 1969 Lt Col John Watts, Royal Irish Rangers 1972 Lt Col Peter de la Billière, Light Infantry 1974 Lt Col Anthony Jeapes, Devonshire and Dorset Regiment 1977 Lt Col Mike Wilkes, Royal Artillery 1982 Lt Col Mike Rose, Coldstream Guards 1984 Lt Col Andrew Massey, Royal Corps of Transport 1986 Lt Col Cedric Delves, Devonshire and Dorset Regiment 1989 Lt Col John Holmes, Scots Guards n/k Lt Col Jonathan "Jacko" Page, Parachute Regiment 2001 Lt Col Ed Butler, Royal Green Jackets 2002 Lt Col Mark Carleton-Smith, Irish Guards 2007 Lt Col Richard Williams, Parachute Regiment 2012 Lt Col Nick Perry, King's Royal Hussars
γ-L-Glutamyl-L-cysteine, also known as γ-glutamylcysteine (GGC), is a dipeptide found in animals, plants, fungi, some bacteria, and archaea. It has a relatively unusual γ-bond between the constituent amino acids, L-glutamic acid and L-cysteine and is a key intermediate in the γ-glutamyl cycle first described by Meister in the 1970s. It is the most immediate precursor to the antioxidant glutathione.
Alitretinoin, or 9-cis-retinoic acid, is a form of vitamin A. It is also used in medicine as an antineoplastic (anti-cancer) agent developed by Ligand Pharmaceuticals. It is a first generation retinoid. Ligand gained Food and Drug Administration (FDA) approval for alitretinoin in February 1999.
Sources: en.wikipedia.org
Reports describe modulation of GABA signalling, changes in monoamine turnover and effects on neurotrophic factor expression. These observations come mainly from animal and cell studies. A single unifying mechanism has not been demonstrated.
The peptide enters plasma rapidly and is broken down by ordinary proteases into amino acids and shorter fragments. Reported half-lives are short. Whether meaningful amounts of the intact molecule reach the brain is an open question.
Most clinical reports are small, published in Russian and not independently replicated. English-language reviews highlight the absence of large randomised trials. Conclusions about efficacy should be treated as provisional.
The most common approach combines reverse-phase liquid chromatography with mass spectrometry. Chromatography separates the components while mass spectrometry confirms the molecular mass. Peptide sequencing or tandem mass analysis can further verify the amino acid order.